


Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

### AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Previously presented) A compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

W<sup>1</sup> is nitrogen or CH, W<sup>2</sup> is nitrogen or C-(U)<sub>p</sub>R<sup>U</sup>, and W<sup>3</sup> is nitrogen or C-(V)<sub>q</sub>R<sup>V</sup>;

p and q are each independently 0 or 1;

R<sup>U</sup> and R<sup>V</sup> are each independently R or Ar<sup>1</sup>;

U and V are each independently a bond or a C<sub>1-6</sub> alkylidene chain, wherein up to two methylene units of the chain are optionally and independently replaced by CO, CO<sub>2</sub>, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO<sub>2</sub>, NRCONR, SO, SO<sub>2</sub>, NRSO<sub>2</sub>, SO<sub>2</sub>NR, NRSO<sub>2</sub>NR, O, S, or NR;


each occurrence of R is independently hydrogen or an optionally substituted C<sub>1</sub>-C<sub>4</sub> aliphatic, or two R bound to the same nitrogen atom are optionally taken together with the nitrogen atom to form a 3-7 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 additional heteroatoms independently selected from nitrogen, oxygen, or sulfur;

Ar<sup>1</sup> is a 5-7 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

sulfur; wherein  $Ar^1$  is optionally substituted with  $m$  independent occurrences of  $Z-R^5$ ; wherein  $m$  is 0-5,  $Z$  is a bond or is a  $C_1-C_n$  alkylidene chain wherein up to two methylene units of  $Z$  are optionally replaced by CO,  $CO_2$ , COCO, CONR, OCONR, NRNR, NRNRCO, NRCO,  $NRCO_2$ , NRCONR, SO,  $SO_2$ ,  $NRSO_2$ ,  $SO_2NR$ ,  $NRSO_2NR$ , O, S, or NR; and each occurrence of  $R^5$  is independently hydrogen, an optionally substituted aliphatic, heteroaliphatic, aryl or heteroaryl group, halogen,  $NO_2$ , CN, OR, SR,  $N(R)_2$ , NRCOR,  $NRCON(R)_2$ ,  $NRCO_2R$ , COR,  $CO_2R$ , OCOR,  $CON(R)_2$ , OCON(R)<sub>2</sub>, SOR,  $SO_2R$ ,  $SO_2N(R)_2$ ,  $NRSO_2R$ ,  $NRSO_2N(R)_2$ , COCOR, or  $COCH_2COR$ ;

$R^1$  and  $R^2$  are taken together and fused to ring B to form a heterocyclic moiety selected from one of formulae (a) through (f):



wherein each occurrence of  $R^X$  is independently hydrogen, QR, or  $Q_nAr^1$ ;  $n$  is zero or one;  
 and  $Q$  is an optionally substituted  $C_{1-4}$  alkylidene chain wherein one methylene unit of  $Q$  is optionally replaced by CO,  $CO_2$ , COCO, CONR, OCONR, NRNR, NRNRCO, NRCO,  $NRCO_2$ , NRCONR, SO,  $SO_2$ ,  $NRSO_2$ ,  $SO_2NR$ ,  $NRSO_2NR$ , O, S, or NR;  
 $R^3$  is hydrogen, halogen, QR,  $Q_nCN$ ,  $Q_nNO_2$ , or  $Q_nAr^1$ ; and  
 $R^4$  is  $Ar^1$ , or  $T-Ar^1$ ;

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

wherein T is a C<sub>1-2</sub> alkylidene chain wherein one methylene unit of T is optionally replaced by CO, CO<sub>2</sub>, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO<sub>2</sub>, NRCONR, SO, SO<sub>2</sub>, NRSO<sub>2</sub>, SO<sub>2</sub>NR, NRSO<sub>2</sub>NR, O, S, or NR.

2. (Previously presented) The compound of claim 1, wherein R<sup>1</sup> and R<sup>2</sup> taken together form the heterocyclic moiety of formula (a) and R<sup>x</sup> is hydrogen or optionally substituted C<sub>1-6</sub> aliphatic.
3. (Original) The compound of claim 1, wherein R<sup>x</sup> is hydrogen, methyl, ethyl, propyl, n-butyl, tert-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, C<sub>1-6</sub>alkyl substituted with N(R)<sub>2</sub>, or C<sub>1-6</sub>alkyl substituted with Ar<sup>1</sup>.
4. (Original) The compound of claim 1, wherein R<sup>x</sup> is hydrogen, methyl, or C<sub>1-6</sub>alkyl substituted with a group selected from optionally substituted phenyl, pyridyl, morpholin, piperidinyl, or piperazinyl.
5. (Original) The compound of claim 1, wherein R<sup>3</sup> is hydrogen, halogen, QR or QAr<sup>1</sup>, wherein Q is a C<sub>1-3</sub> alkylidene chain wherein one methylene unit of Q is optionally replaced by -O-, -S-, -NHCO-, or -NR-, and Ar<sup>1</sup> is an optionally substituted 5-6 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
6. (Original) The compound of claim 1, wherein R<sup>3</sup> is hydrogen, OH, OCH<sub>3</sub>, OCH<sub>2</sub>CH<sub>3</sub>, NHCOMe, NH<sub>2</sub>, NH(C<sub>1-4</sub> aliphatic), N(C<sub>1-4</sub> aliphatic)<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>morpholin-4-yl, O(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>NH(C<sub>1-4</sub> aliphatic), O(CH<sub>2</sub>)<sub>2</sub>N(C<sub>1-4</sub> aliphatic)<sub>2</sub>, Br, Cl, or F.
7. (Original) The compound of claim 1, wherein R<sup>3</sup> is hydrogen.

Applicants: Randy S. Berthel et al.  
Application No.: 10/700,936

8. (Original) The compound of claim 1, wherein  $R^4$  is a 6-membered saturated, partially unsaturated, or aryl ring having 0-3 nitrogens, a 9-10 membered bicyclic aryl ring having 0-2 nitrogen atoms, or a 5 membered heteroaryl ring having 2-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein each ring is optionally substituted.

9. (Original) The compound of claim 1, wherein  $R^4$  is optionally substituted phenyl, cyclohexyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, thiazolyl, thiadiazolyl, pyrazolyl, isoxazolyl, indazolyl, or benzimidazolyl.

10. (Original) The compound of claim 1, wherein  $R^4$  is an optionally substituted phenyl group.

11. (Original) The compound of claim 8, wherein each occurrence of Z is independently a bond or a  $C_{1-4}$  alkylidene chain wherein one methylene unit of Z is optionally replaced by -O-, -S-, -SO<sub>2</sub>-, or -NH-; and each occurrence of  $R^5$  is independently hydrogen,  $C_{1-6}$  aliphatic, halogen, NO<sub>2</sub>, OR, N(R)<sub>2</sub>, or optionally substituted phenyl, pyridyl, or pyrimidinyl.


12. (Previously presented) The compound of claim 8, wherein each occurrence of  $ZR^5$  is independently Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt, CF<sub>3</sub>, NH<sub>2</sub>, phenyl, benzyl, benzyloxy, OH, methylenedioxy, SO<sub>2</sub>NH<sub>2</sub>, CONH<sub>2</sub>, CO<sub>2</sub>Me, phenoxy, O-pyridinyl, SO<sub>2</sub>phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, phenol, chloro-fluoro-phenyl, dimethylaminophenyl, CF<sub>3</sub>-phenyl, dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, and fluorophenoxy.

13. (Original) The compound of claim 1, wherein  $(U)_pR^U$  and  $(V)_qR^V$  are each independently hydrogen, halogen, NO<sub>2</sub>, CN, OR, SR or N(R)<sub>2</sub>, or  $C_{1-4}$  aliphatic optionally substituted with oxo, OR, SR, N(R)<sub>2</sub>, halogen, NO<sub>2</sub> or CN.


Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

14. (Original) The compound of claim 1, wherein  $(U)_pR^U$  and  $(V)_qR^V$  are each independently hydrogen, Me, OH, or OMe.

15. (Original) The compound of claim 1, wherein  $W^1$  is N or CH and compounds have the structure of Formula Ia or Ib:




Ia




Ib

or a pharmaceutically acceptable salt thereof.

16. (Previously presented) The compound of claim 15, wherein  $R^4$  is an optionally substituted phenyl group and compounds have the structure of Formula IIa or IIb:



IIa





IIb

or a pharmaceutically acceptable salt thereof.



17. (Previously presented) The compound of claim 16, wherein  $R^3$  is hydrogen, and compounds have the structure of Formula IIIa or IIIb:

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936



or a pharmaceutically acceptable salt thereof.

18. (Previously presented) The compound of claim 16, wherein  $R^3$  is hydrogen, and  $R^1$  and  $R^2$  taken together form the heterocyclic moiety of formula (a) and compounds have the structure of Formula IVa or IVb:



or a pharmaceutically acceptable salt thereof.

19. (Previously presented) The compound of claim 15, wherein  
 i)  $R^1$  and  $R^2$  taken together form the heterocyclic moiety of formula (a); where  $R^x$  is defined according to one of the following groups:

- (a) hydrogen or optionally substituted  $C_{1-6}$ aliphatic;
- (b) hydrogen, methyl, ethyl, propyl, n-butyl, tert-butyl, pentyl, cyclopentyl, hexyl, cyclohexyl,  $C_{1-6}$ alkyl substituted with  $N(R)_2$ , or  $C_{1-6}$ alkyl substituted with  $Ar^1$ ; or

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

(c) hydrogen, methyl, or  $C_{1-7}$  alkyl substituted with a group selected from optionally substituted phenyl, pyridyl, morpholino, piperidinyl, or piperazinyl.

ii)  $R^3$  is defined according to one of the following groups:

- (a) hydrogen, halogen, QR or  $QAr^1$ , wherein Q is a  $C_{1-3}$  alkylidene chain wherein one methylene unit of Q is optionally replaced by -O-, -S-, -NHCO-, or -NR-, and  $Ar^1$  is an optionally substituted 5-6 membered saturated, partially unsaturated, or fully unsaturated ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- (b) hydrogen, OH,  $OCH_3$ ,  $OCH_2CH_3$ ,  $NHCOMe$ ,  $NH_2$ ,  $NH(C_{1-4} \text{ aliphatic})$ ,  $N(C_{1-4} \text{ aliphatic})_2$ ,  $O(CH_2)_2\text{morpholin-4-yl}$ ,  $O(CH_2)_2NH_2$ ,  $O(CH_2)_2NH(C_{1-4} \text{ aliphatic})$ ,  $O(CH_2)_2N(C_{1-4} \text{ aliphatic})_2$ , bromo, chloro, or fluoro; or
- (c) hydrogen;

iii)  $R^4$  is defined according to one of the following groups:

- (a) a 6-membered saturated, partially unsaturated, or aryl ring having 0-3 nitrogens, a 9-10 membered bicyclic aryl ring having 0-2 nitrogens, or a 5 membered heteroaryl ring having 2-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein said ring is optionally substituted with  $(ZR^5)_m$ ;
- (b) an optionally substituted ring selected from phenyl, cyclohexyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, thiazolyl, thiadiazolyl, pyrazolyl, isoxazolyl, indazolyl, or benzimidazolyl, wherein said ring is optionally substituted with  $(ZR^5)_m$ ; or
- (c) an optionally substituted phenyl group, wherein said phenyl group is optionally substituted with  $(ZR^5)_m$ ;

iv)  $W^1$ ,  $W^2$  and  $W^3$  are defined according to one of the following groups:

- (a)  $W^1$  is nitrogen or CH,  $W^2$  is nitrogen or  $C-(U)_pR^U$ , and  $W^3$  is nitrogen or  $C-(V)_qR^V$ ;

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936

- (b)  $W^1$  is nitrogen or CH,  $W^2$  is  $C-(U)_pR^U$ , and  $W^3$  is  $C-(V)_qR^V$ ; or
- (c)  $W^1$  is nitrogen or CH and  $W^2$  and  $W^3$  are each CH; and
- v)  $(U)_pR^U$  and  $(V)_qR^V$  groups are defined according to one of the following groups:
  - (a) hydrogen, halogen,  $NO_2$ , CN, OR, SR or  $N(R)_2$ , or  $C_{1-4}$  aliphatic optionally substituted with oxo, OR, SR,  $N(R)_2$ , halogen,  $NO_2$  or CN;
  - (b) hydrogen, Me, OH, OMe or  $N(R)_2$ ; or
  - (c) both  $(U)_pR^U$  and  $(V)_qR^V$  are hydrogen.

20. (Previously presented) The compound of any one of claims 16, 17, 18 or 19, wherein each occurrence of Z is independently a bond or a  $C_{1-4}$  alkylidene chain wherein one methylene unit of Z is optionally replaced by -O-, -S-, - $SO_2$ -, or -NH-; and each occurrence of  $R^5$  is independently hydrogen,  $C_{1-6}$  aliphatic, halogen,  $NO_2$ , OR,  $N(R)_2$ , or optionally substituted phenyl, pyridyl, and pyrimidinyl.

21. (Previously presented) The compound of claim 20, wherein each occurrence of  $ZR^d$  is independently Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt,  $CF_3$ ,  $NH_2$ , phenyl, benzyl, benzyloxy, OH, methylenedioxy,  $SO_2NH_2$ ,  $CONH_2$ ,  $CO_2Me$ , phenoxy, O-pyridinyl,  $SO_2$ phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, phenol, chloro-fluoro-phenyl, dimethylaminophenyl,  $CF_3$ -phenyl, dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, or fluorophenoxy.


22. (Previously presented) The compound of claim 18 having the formula IVa, wherein  $R^x$  is hydrogen or optionally substituted  $C_{1-6}$  aliphatic; m is 0, 1 or 2; and  $ZR^d$  is Cl, F, Br, methyl, ethyl, t-butyl, isopropyl, cyclopropyl, nitro, CN, OMe, OEt,  $CF_3$ ,  $NH_2$ , phenyl, benzyl, benzyloxy, OH, methylenedioxy,  $SO_2NH_2$ ,  $CONH_2$ ,  $CO_2Me$ , phenoxy, O-pyridinyl,  $SO_2$ phenyl, nitrophenoxy, aminophenoxy, S-dimethylpyrimidine, NHphenyl, NH-methoxyphenyl, pyridinyl, phenol, chloro-fluoro-phenyl, dimethylaminophenyl,  $CF_3$ -phenyl,




Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

dimethylphenyl, chlorophenyl, fluorophenyl, methoxyphenoxy, chlorophenoxy, ethoxyphenoxy, or fluorophenoxy.


23. (Previously presented) The compound of claim 1, selected from one of the following compounds:




IVa-1




IVa-2




IVa-3




IVa-4




IVa-5




IVa-6




IVa-7




IVa-8




IVa-9



IVa-10




IVa-11




IVa-12


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-13




IVa-14




IVa-15




IVa-16




IVa-17




IVa-18




IVa-19




IVa-20




IVa-21



IVa-22




IVa-23




IVa-24


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-25




IVa-26




IVa-27




IVa-28




IVa-29




IVa-30




IVa-31




IVa-32




IVa-33




IVa-34



IVa-35




IVa-36




IVa-37


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-38




IVa-39




IVa-40




IVa-41




IVa-42




IVa-43




IVa-44




IVa-45




IVa-46



IVa-47




IVa-48




IVa-49


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-50




IVa-51




IVa-52




IVa-53




IVa-54




IVa-55




IVa-56



IVa-57




IVa-58




IVa-59


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-60




IVa-61




IVa-62




IVa-63




IVa-64




IVa-65



IVa-66




IVa-67




IVa-68


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVa-69




IVa-70




IVa-71




IVa-72




IVb-1




IVb-2




IVb-3



IVb-4




IVb-5




IVb-6


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-7




IVb-8




IVb-9




IVb-10




IVb-11




IVb-12




IVb-13




IVb-14




IVb-15



IVb-16




IVb-17




IVb-18




Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-19




IVb-20




IVb-21




IVb-22




IVb-23




IVb-24




IVb-25




IVb-26




IVb-27



IVb-28




IVb-29




IVb-30


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-31




IVb-32




IVb-33




IVb-34




IVb-35




IVb-36




IVb-37




IVb-38




IVb-39



IVb-40




IVb-41




IVb-42


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-43




IVb-44




IVb-45




IVb-46




IVb-47




IVb-48




IVb-49



IVb-50




IVb-51




IVb-52


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-53




IVb-54




IVb-55




IVb-56




IVb-57




IVb-58




IVb-59



IVb-60




IVb-61




IVb-62


Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936




IVb-63




IVb-64




IVb-65




IVb-66




IVb-67




IVb-68



IVb-69




IVb-70



IVb-71

Applicants: Randy S. Bethiel et al.  
 Application No.: 10/700,936



or IVb-72.

24. (Original) A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

25. (Canceled)

26. (Currently amended) A method of inhibiting JAK-3 kinase activity in a biological sample; [[:]]

~~(a) a patient; or~~

~~(b) a biological sample;~~

which method comprises ~~administering to said patient, or contacting said biological sample with a compound of claim 1 or a composition comprising said compound.~~

27. (Canceled)

28. (Currently amended) A method of treating or lessening the severity of a ~~The method of claim 27, wherein the disease or disorder [[:]] selected from an allergic or type I hypersensitivity reaction, asthma, transplant rejection, graft versus host disease, rheumatoid arthritis, amyotrophic lateral sclerosis, multiple sclerosis, Familial amyotrophic lateral sclerosis (FALS), or leukemia, or lymphoma comprising administering to a subject in need thereof a compound of claim 1 or a composition comprising said compound.~~

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

29. The method of claim 28, comprising the further step of administering to said patient an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, ~~a treatment for Alzheimer's Disease, a treatment for Parkinson's Disease, an agent for treating Multiple Sclerosis (MS),~~ a treatment for asthma, ~~an agent for treating schizophrenia,~~ an anti-inflammatory agent, ~~or an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating destructive bone disorder, an agent for treating liver disease, an agent for treating a blood disorder, or an agent for treating an immunodeficiency disorder,~~ wherein

said additional therapeutic agent is appropriate for the disease being treated; and  
said additional therapeutic agent is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.